Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) - Full Text View

Purpose

The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.

Condition	Intervention	Phase
Cardiovascular Disease Coronary Artery Bypass Surgery	Drug: Angiomax (bivalirudin)	Phase III

MedlinePlus related topics:

Blood Thinners Coronary Artery Bypass Surgery

Drug Information available for:

Heparin Bivalirudin Protamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)

Further study details as provided by The Medicines Company:

Estimated Enrollment:	150
Study Start Date:	April 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Provide written informed consent before initiation of any study related procedures.
Be at least 18 years of age.
Be scheduled for CABG, CABG and single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo) CABG are also considered eligible for this study.

Exclusion Criteria

Confirmed pregnancy at time of randomization via IVRS (if woman of child-bearing potential) (Urine or serum pregnancy test)
Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit.
Intracranial neoplasm, arteriovenous malformation or aneurysm.
Dependency on renal dialysis or creatinine clearance <30 mL/min.
Ongoing treatment with warfarin (or other oral anticoagulant) at the time of randomization.

Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is < 1.3 times control in the absence of heparin therapy.

Known allergy to Angiomax or hirudin-derived drugs, or known sensitivity to any component of the product.
Patients receiving clopidogrel (Plavix®) within the previous 5 days of randomization
Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours if abciximab (ReoPro®) or 24 hours if eptifibatide (Integrilin®) or tirofiban (Aggrastat®) of randomization.
Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours prior to randomization.
Patients receiving LMWH or thrombolytics within the previous 12 hours or unfractionated heparin within 30 minutes of randomization.
Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization.
Refusal to undergo blood transfusion should it become necessary.
Any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial.
Planned surgical procedure in which proximal anastomoses will precede distal anastomoses of the bypass grafts.
Planned (>1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079586

Locations


United States, Ohio
	The Cleveland Clinic
	Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

The Medicines Company

Investigators


Study Director:	Malcolm Lloyd, MD	The Medicines Company

More Information

Study ID Numbers:	TMC-BIV-02-06, EVOLUTION-On
First Received:	March 9, 2004
Last Updated:	March 16, 2006
ClinicalTrials.gov Identifier:	NCT00079586
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Bivalirudin

Protamines

Heparin

Calcium heparin

Additional relevant MeSH terms:

Anticoagulants

Therapeutic Uses

Hematologic Agents

Cardiovascular Diseases

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	The Medicines Company
Information provided by:	The Medicines Company
ClinicalTrials.gov Identifier:	NCT00079586